Promising asthma trial prompts Regeneron, Sanofi to push dupilumab into PhIII – FierceBiotech


Reuters

Promising asthma trial prompts Regeneron, Sanofi to push dupilumab into PhIII
FierceBiotech
Regeneron and its close partner Sanofi have cleared the final mid-stage hurdle for dupilumab in asthma patients, with several doses hitting the trial endpoint both for a subset of patients as well as the broad population. And the ambitious development
Sanofi's dual-action biotech asthma drug performs well in testReuters
Positive results for Sanofi/Regeneron's dupilumab in asthmaThe Pharma Letter

all 29 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.